Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Black Diamond Therapeutics announced that it will present Phase 2 data for silevertinib at the 2026 ASCO Annual Meeting, including an oral session on treatment-naïve NSCLC patients. Additional poster presentations will cover safety and efficacy results in previously treated NSCLC patients and a trial-in-progress update for newly diagnosed EGFRvIII-positive glioblastoma.
Key figures
- Drug Name
- Silevertinib (BDTX-1535)
- Phase Of Trial
- Phase 2
- Dcr
- 91%
- Orr
- 60%
- Cns orr
- 86%
- Patients treated
- over 200
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.